102 completed, 35 recruiting, 24 terminated, 11 unknown. 194 Phase 1, 77 Phase 2.
Follow Blood Platelet Disorders: new trials by email Literature Review of Blood Platelet Disorders trials Research Report on Blood Platelet Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 1 Dose Escalation Study of RXIM002 in Autoimmune Cytopenias RXIM002 - Immune Thrombocytopenia (ITP) | Phase 1 | Not yet recruiting | RiboX Therapeutics Ltd. | 27 | 2027-02-01 | 2026-10-28 |
| An Open-label Phase I/II Safety and Feasibility Basket Study of UKT-CART19.1 CAR-T cells targeting CD19 - Pemphigus Vulgaris (PV), ANCA Associated Vasculitis (AAV) | Phase 1 / Phase 2 | Not yet recruiting | University Hospital Tuebingen | 36 | 2027-01-01 | 2026-11-12 |
| A Phase 1b/2a Study of Velinotamig in Adults With Relapsed/Refractory ITP and wAIHA Velinotamig specified dose on specified days. - Immune Thrombocytopenia (ITP), Warm Autoimmune Hemolytic Anemia (WAIHA) | Phase 1 / Phase 2 | Not yet recruiting | Cullinan Therapeutics Inc. | 72 | 2026-12-01 | 2026-07-31 |
| TGD001 Treatment in Thrombotic Microangiopathies TGD001 - Thrombotic Microangiopathies, ITP Immune-Mediated Thrombocytopenia | Phase 1 / Phase 2 | Recruiting | TargED Biopharmaceuticals B.V. | 70 | 2026-10-25 | 2026-11-12 |
| A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative Neoplasms DMR-001, Ruxolitinib - Myeloproliferative Neoplasms (MPNs) | Phase 1 | Recruiting | Damora Therapeutics | 250 | 2026-09-01 | 2026-10-27 |
| Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease CTX112 - Warm Autoimmune Hemolytic Anemia (WAIHA), ITP - Immune Thrombocytopenia | Phase 1 / Phase 2 | Recruiting | CRISPR Therapeutics AG | 60 | 2026-07-17 | 2026-10-20 |
| Bioequivalence Study of SKI-O-703 in Healthy Adults Under Fed Conditions SKI-O-703 API in Capsules, SKI-O-703 Formulated Granules in Capsules - Bioequivalence Study in Healthy Subjects, Immune Thrombocytopenia (ITP) | Phase 1 | Active not recruiting | Oscotec Inc. | 48 | 2026-07-10 | 2026-09-01 |
| A Clinical Study to Evaluate JCXH-213 in the Treatment of Adults With Primary Immune Thrombocytopenia JCXH-213 - Thrombocytopenic Purpura, Immune | Phase 1 | Recruiting | The General Hospital of Western Theater Command | 4 | 2026-06-18 | 2026-11-17 |
| CD20 Monoclonal Antibody Combined With BTK Inhibitor for the Treatment of Refractory Immune-related Cytopenia Anti-CD20 monoclonal antibody and the BTK inhibitor - Anti-CD20 Monoclonal Antibody, BTK Inhibitors | Phase 1 | Not yet recruiting | Qi deng | 30 | 2026-06-01 | 2026-05-22 |
| Therapeutic RSK1 Targeting in Myeloid Malignancies PMD-026 - Myeloid Malignancy | Phase 1 | Recruiting | Washington University School of Medicine | 30 | 2026-05-20 | 2026-10-21 |
| Universal STAR-T Cell Injection in R/R Autoimmune Diseases. Universal STAR-T Cell - Immune Thrombocytopenia | Phase 1 | Not yet recruiting | Jian Zhu | 6 | 2026-05-11 | 2026-05-20 |
| Study of INCA036978 in Participants With Myeloproliferative Neoplasms INCA036978, Standard disease-directed therapy - Myeloproliferative Neoplasms | Phase 1 | Recruiting | Incyte Corporation | 218 | 2026-05-11 | 2026-11-13 |
| Safety and Tolerability of ZE74-0282 in Healthy Volunteers ZE74-0282-0001 or placebo - Healthy Volunteers | Phase 1 | Recruiting | Eilean Therapeutics AU Pty Ltd | 64 | 2026-04-16 | 2026-07-28 |
| Safety and Efficacy of GL-2045 in Patients With Immune Thrombocytopenia GL-2045 - Immune Thrombocytopenia | Phase 1 | Recruiting | Gliknik Inc. | 42 | 2026-04-14 | 2026-05-26 |
| A Study of CM336 in Patients With Relapsed or Refractory Autoimmune Cytopenia CM336 Injection - Autoimmune Cytopenia, Immune Thrombocytopenia (ITP) | Phase 1 / Phase 2 | Recruiting | Keymed Biosciences Co.Ltd | 158 | 2025-11-18 | 2025-12-17 |
| Phase I Study of SHR-2173 Injection in Patients With Primary Immune Thrombocytopenia SHR-2173 Injection - Immune Thrombocytopenia | Phase 1 | Recruiting | Guangdong Hengrui Pharmaceutical Co., Ltd | 10 | 2025-11-12 | 2026-05-28 |
| An Exploratory Study of Golidocitinib in Adult Patients With ITP Golidocitinib, Placebo - Immune Thrombocytopenia (ITP) | Phase 1 / Phase 2 | Not yet recruiting | Peking University People's Hospital | 138 | 2025-10-30 | 2025-09-29 |
| A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms INCA035784 - Myeloproliferative Neoplasms | Phase 1 | Recruiting | Incyte Corporation | 120 | 2025-10-01 | 2026-08-06 |
| Umbilical Cord Blood Megakaryocyte Injection (XJ-MK-002) for Cancer Therapy-Induced Thrombocytopenia (CTIT) Umbilical Cord Blood Megakaryocyte Injection (XJ-MK-002) - Thrombocytopenia, Cancer | Phase 1 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 16 | 2025-08-28 | 2025-09-09 |
| OM336 in Autoimmune Cytopenias OM336 - AIHA - Warm Autoimmune Hemolytic Anemia, AIHA - Cold Autoimmune Hemolytic Anemia | Phase 1 | Recruiting | Lakefront Biotherapeutics West LLC | 32 | 2025-08-01 | 2026-09-03 |
Showing 20 of 194. Sign in to see all of them.
Thrombocythemia, Essential (68) · Primary Myelofibrosis (67) · Purpura, Thrombocytopenic, Idiopathic (63) · Polycythemia Vera (59) · Myeloproliferative Disorders (58) · Thrombocytopenia (49) · Leukemia, Myeloid, Acute (44) · Leukemia, Myelomonocytic, Chronic (40) · Myelodysplastic Syndromes (38) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (35) · Leukemia, Lymphocytic, Chronic, B-Cell (33) · Leukemia (32) · Multiple Myeloma (28) · Lymphoma, Non-Hodgkin (27) · Burkitt Lymphoma (26)
Hemic and Lymphatic Diseases (194) · Hematologic Diseases (184) · Hemorrhagic Disorders (144) · Blood Coagulation Disorders (142) · Pathological Conditions, Signs and Symptoms (129) · Pathologic Processes (128) · Cytopenia (109) · Immune System Diseases (109) · Bone Marrow Diseases (80) · Neoplasms (76) · Neoplasms by Site (67) · Signs and Symptoms (67) · Hemorrhage (66) · Skin Manifestations (65)
eltrombopag (15) · ruxolitinib (12) · Peripheral Blood Stem Cell Transplantation (11) · Cyclosporine (9) · fludarabine phosphate (7) · Busulfan (6) · Carboplatin (6) · Cyclophosphamide (6) · Filgrastim (6) · Antilymphocyte Serum (5) · Cytarabine (5) · Decitabine (5) · Etoposide (5) · romiplostim (5) · Methotrexate (4)
National Cancer Institute (NCI) (9) · GlaxoSmithKline (7) · Incyte Corporation (6) · Eisai Inc. (5) · Amgen (4) · Chongqing Peg-Bio Biopharm Co., Ltd. (4) · Eli Lilly and Company (4) · Fred Hutchinson Cancer Center (4) · Peking University People's Hospital (4) · M.D. Anderson Cancer Center (3) · National Heart, Lung, and Blood Institute (NHLBI) (3) · Protalex, Inc. (3) · Bioverativ, a Sanofi company (2) · California Cancer Consortium (2) · Case Comprehensive Cancer Center (2)
United States (124) · China (35) · United Kingdom (22) · Australia (19) · Germany (17) · Italy (17) · France (15) · Spain (15) · Canada (13) · Belgium (8) · Netherlands (7) · Poland (7) · Austria (6) · Denmark (6) · Japan (6)
Ayalew Tefferi, MD (2) · Brenda Cooper, MD (2) · Franklin Johnson (2) · Jacob H Grauslund, MD (2) · Jorge Cortes, MD (2) · Qiubai Li, Professor (2) · Richard K. Burt, MD (2) · Ronald Hoffman, MD (2)
PMID 15570084, PMID 15814645, PMID 17880439, PMID 19208097, PMID 19846889, PMID 20843246, PMID 20955619, PMID 22259028, PMID 22718840, PMID 23131255, PMID 23497336, PMID 23777763, PMID 23829485, PMID 24120380, PMID 24474568, PMID 24802773, PMID 25563429, PMID 25621498, PMID 25762180, PMID 26210442, PMID 26354756, PMID 26504182, PMID 26686043, PMID 26853648, PMID 27479177, PMID 27515248, PMID 28934680, PMID 29270980, PMID 29419434, PMID 29544547, PMID 29674506, PMID 29958797, PMID 30171280, PMID 30204953, PMID 30344993, PMID 30562587, PMID 31167802, PMID 32476546, PMID 32634234, PMID 32865293, PMID 33410523, PMID 33718228, PMID 33910334, PMID 34219224, PMID 34452956, PMID 34525188, PMID 34724566, PMID 34921514, PMID 35973190, PMID 36881782
2018 (4), 2014 (2), 2023 (2), P30CA015083 (2), P30CA016058 (2), U01CA062491 (2), 2005 (1), 2019 (1), 2025 (1), P01CA015396 (1), P01CA018029 (1), P01CA108671 (1), P30CA006973 (1), P30CA016086 (1), P30CA016087 (1)